NHS Logo
Image from Google Jackets

SITC's Guide to Managing Immunotherapy Toxicity

By: Contributor(s): Publication details: United States : Springer, 2019ISBN:
  • 0826172148
  • 9780826172143
Subject(s):
Contents:
Overview of Anti-CLA-4 agents - ipilimunab and tremelimumab; Overview of PD-1 and PD-L1 inhibitors; Indication and toxicities of immune checkpoint inhibitor combinations; General principles of immune-related toxicities; Dermatologic toxicities - rash, mucosal irritation, and pruritus; Muskuloskeletal and rheumatologic toxicities; Immune-related gastrointestinal toxicities; Pneumotoxicity associated with immune checkpoint blockades; Immune-related endocrinopathies associated with immune checkpoint inhibitors; Neurologic adverse events and neurologic complications; Cardiovascular toxicities related to immune checkpoint inhibitors; Renal toxicities associated with immune checkpoint inhibitors; Haematologic toxicities of apparent immune-related origins; Ocular toxicities caused by immune dysregulation; Safety and regulation of immune checkpoint inhibitors in special patient populations; Cancer-related fatigue in patients of immune checkpoint inhibitor therapy; Cost-effectiveness and financial toxicity of new cancer therapies
Summary: SITC's Guide to Managing Immunotherapy Toxicity is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Home library Class number Status Date due Barcode
Book David Adams Library (Royal Marsden) Shelves QZ200 ERN (Browse shelf(Opens below)) Available 0000007682

Overview of Anti-CLA-4 agents - ipilimunab and tremelimumab; Overview of PD-1 and PD-L1 inhibitors; Indication and toxicities of immune checkpoint inhibitor combinations; General principles of immune-related toxicities; Dermatologic toxicities - rash, mucosal irritation, and pruritus; Muskuloskeletal and rheumatologic toxicities; Immune-related gastrointestinal toxicities; Pneumotoxicity associated with immune checkpoint blockades; Immune-related endocrinopathies associated with immune checkpoint inhibitors; Neurologic adverse events and neurologic complications; Cardiovascular toxicities related to immune checkpoint inhibitors; Renal toxicities associated with immune checkpoint inhibitors; Haematologic toxicities of apparent immune-related origins; Ocular toxicities caused by immune dysregulation; Safety and regulation of immune checkpoint inhibitors in special patient populations; Cancer-related fatigue in patients of immune checkpoint inhibitor therapy; Cost-effectiveness and financial toxicity of new cancer therapies

SITC's Guide to Managing Immunotherapy Toxicity is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs

There are no comments on this title.

to post a comment.
London Health Libraries Consortium Privacy notice and Membership terms and conditions